8:50 am Chair’s Opening Remarks
Reflecting on Progress: Positive Clinical Readouts, Reverse Insights & Actionable Lessons for Glioblastoma Drug Developers
9:00 am Positive Clinical Updates on Vaccine-Based Approaches; Uncovering their Potential in Combination Therapy
Synopsis
- SurVaxM – a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine targeting surviving
- Phase IIa study of surVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma
9:30 am Outlining the Landscape in Paediatric Glioma & Delving Into Recent Successes
Synopsis
- Highlighting opportunities and challenges in developing therapeutics for elapsed or progressive paediatric low-grade glioma (pLGG).
- Navigating the dual challenges of a shifting landscape for response assessment criteria and changing views on minor response as evidence of clinical benefit.
- Targeting beyond the MAPK in paediatric glioma.
10:00 am Morning Break & Speed Networking
Synopsis
The ideal opportunity to get face-to-face with many of the brightest minds working in the GBM field and introduce yourself to the attendees that you would like to have more in depth conversations with.
11:00 am Sharing an Update From Polaris – ADI-PEG 20 in Glioblastoma: Preclinical Studies & Phase I-II Results
Synopsis
- Review preclinical studies and phase I results
- Gain an update on phase II and phase II/III studies
- Discuss the initiation of ADI-PEG 20 into GBM agile
11:30 am Delving into a Clinical Update on Azeliragon for GBM- Implementable Lessons for Small Molecule Success
Synopsis
- In animal models of glioblastoma, azeliragon combined with radiation enhanced survival while overcoming the immunosuppressive tumor microenvironment
- Two phase II clinical trials of azeliragon, in combination with radiation with or without temozolomide, in newly diagnosed glioblastoma are in progress
- The effect of azeliragon on cerebral edema and ability to reduce dexamethasone dosing will be evaluated in the azeliragon studies in GBM
Surpassing the Blood Brain Barrier to Unlock the Potential of New Therapeutic Agents
12:00 pm Discovering Innovative Ultrasound Techniques to Open Up New Avenues for Treating Glioblastoma
Synopsis
- Discover the use of low intensity diffuse ultrasound with sonodynamic therapy to treat glioblastoma with both short and long-term effects
- Understand the suspected mechanism of action of sonodynamic therapy
- Understand and overcome the pitfalls in currently available brain cancer treatments
12:30 pm Exploring Local Drug Delivery in GBM: Enhanced Efficacy of ‘Compartment-Locked’ IL-12
Synopsis
- Evaluating the next generation of local therapies for brain cancer
- Discussing Compartment-Locked therapeutics with high retention and short systemic half-life
- Reviewing C-Locked IL-12 a promising new drug candidate
1:00 pm Lunch
Optimizing Clinical Trial Design for GBM – Uncovering Past Lessons to Redefine Future Trial Outcomes
2:00 pm Gain Unrivalled Insights Into GBM-Specific Clinical Trial Rationale to Keep Ahead of the Curve
Synopsis
- Overview of the updated response criteria for glioblastomas and IDH-mutated gliomas: RANO 2.0
- Sharing therapeutic modality-specific advice on clinical trial design
- Analyzing novel endpoints for glioma trials
2:30 pm Going Beyond the Backbone; An Update on Recent Innovations in GBM Agile
Synopsis
- Integrating dose finding into GBM Agile
- Opportunities to consider the LE (learning environment) in AGILE
- Approaches to addressing combination therapy in GBM Agile
3:00 pm Expert-Led Advice on GBM Clinical Trial Structure to Set Your Trial Up for Success
Synopsis
- Discuss how to optimally leverage external control data to set your trial up for success
- Maximize the opportunity of adaptive platform trials for accelerated success
- Answer your burning questions around clinical trial rationale
3:30 pm Afternoon Break & Networking
Reflecting on Progress: Positive Clinical Readouts, Reverse Insights & Actionable Lessons for Glioblastoma Drug Developers
4:00 pm Addressing Tumor Heterogeneity & Multiple Cellular States: Is Combination Targeted Therapy the Answer?
Synopsis
- Unveiling research into the complexity of tumor heterogeneity in GBM
- Reviewing preclinical data of one approach combining CT-179, an OLIG2 inhibitor, with EGFR inhibitors
- Exploring areas of potential research to identify and test scientifically rational combinations of targeted therapeutics
4:30 pm Panel Discussion: Is Prioritizing Combination Therapy Over Monotherapy the Most Promising Avenue for Overcoming Heterogeneity?
Synopsis
- Understand the shortfalls of key therapy types with regard to targeting tumor heterogeneity and how combination therapies can be used to strategically overcome these
- Combine drug treatments with radiotherapy or tumor treating fields
- Are combination therapies considered ‘too risky’ from a regulatory standpoint?
- Understand how the regulatory framework can best support the approval of combination therapies
5:30 pm Chair’s Closing Remarks
5:35 pm Scientific Poster Presentation
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of GBM experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.